AbbVie Inc. (ETR:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 282.04B |
| Revenue (ttm) | 53.08B |
| Net Income (ttm) | 3.84B |
| Shares Out | n/a |
| EPS (ttm) | 2.16 |
| PE Ratio | 73.37 |
| Forward PE | 14.66 |
| Dividend | 5.88 (3.69%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 111 |
| Average Volume | 338 |
| Open | 159.00 |
| Previous Close | 160.60 |
| Day's Range | 158.60 - 160.00 |
| 52-Week Range | 147.60 - 204.45 |
| Beta | 0.49 |
| RSI | 38.78 |
| Earnings Date | Jul 25, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in em...
My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys
Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment st...
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di...
3 dividend stocks investors can look for stability as Iran attacks US base in Qatar
US stocks could see pressure this week after Iran struck US bases in Qatar in retaliation for President Trump's airstrike on Tehran's nuclear facilities. Amidst the geopolitical backdrop that seems to...
J&J, AbbVie get EU endorsement for Imbruvica's expanded approval
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...
AbbVie declares $1.64 dividend
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happe...
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
AbbVie Inc (NYSE: ABBV) on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared...
AbbVie succeeds in late-stage migraine treatment trial
AbbVie's migraine drug meets main goal of late-stage study
AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.
AbbVie's migraine drug meets main goal in head-to-head study with topiramate
The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, to show a lower discontinuation rate due to undesired effect from the treatment than topiramate. The European...
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migrain...
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migrain...
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Caris Life Sciences , an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie Inc (NYSE: ABBV) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndro...
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.
AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow
Genentech Provides Update on Phase III Verona Study
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) investigating Venclexta (venetoclax) plus azac...
AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax
AbbVie says blood cancer drug fails late-stage trial
AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagno...